Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica's Compensation Committee granted David Zawitz, Verrica's new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company's Inducement Plan, effective December 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz's employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4).
賓夕法尼亞州西切斯特，2024年12月9日（環球新聞）——Verrica製藥公司（"Verrica"或"公司"）（納斯達克：VRCA），一家開發需要醫療干預的皮膚病藥物的皮膚科學治療公司，今天宣佈Verrica的薪酬委員會授予David Zawitz，Verrica的新任首席運營官，一項非合格股票期權，允許他根據公司的引導計劃購買950,000股普通股，生效日期爲2024年12月9日。該股票期權是爲了作爲Zawitz先生加入Verrica的實質性誘因而授予的，符合納斯達克上市規則5635(c)(4)。
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Verrica (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Verrica, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
引導計劃僅用於向之前不是Verrica的員工或非員工董事的個人授予股權獎勵（或在經過真正的非就業期後），作爲這些個人加入Verrica工作的重要誘因，依據納斯達克上市規則5635(c)(4)。
The option award will have an exercise price equal to the closing price of Verrica's common stock on December 9, 2024. The option award will vest and become exercisable as to 1/8th of the shares on the date that is six months following Mr. Zawitz's start date, and 1/48th of the shares each month thereafter on the same day of the month as the start date, subject to Mr. Zawitz's continuous service with Verrica on such vesting dates. The option award is subject to the terms and conditions of the Inducement Plan, and the terms and conditions of a stock option agreement covering the grant.
股票期權的行使價格等於2024年12月9日Verrica普通股的收盤價。股票期權將於Zawitz先生的開始控件日期後的六個月時自動生效，針對1/8的股份生效，此後每個月在與開始控件日期相同的日期對1/48的股份生效，前提是Zawitz先生在相關生效日期與Verrica保持持續服務。股票期權適用引導計劃的條款和條件，以及覆蓋該授予的股票期權協議的條款和條件。
About Verrica Pharmaceuticals Inc.
關於Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit .
verrica製藥是一家開發皮膚病醫療治療藥物的醫療公司。verrica的產品YCANTH (VP-102) (cantharidin)是美國 FDA 批准用於治療兩歲及以上的成人和兒童患者的首個商業化治療選項，該產品適用於羊皮癬，一種高度傳染性的病毒性皮膚感染，影響着美國大約600萬人，主要是兒童。YCANTH (VP-102)還在研發中，用於治療普通疣和外生殖器疣，這兩種是醫療皮膚科領域最大的未滿足需求之一。verrica還在開發其第二個基於cantharidin的產品候選VP-103，用於治療足底疣。verrica還與Lytix Biopharma AS簽訂了全球許可協議，開發和銷售VP-315 (以前稱爲LTX-315和VP-LTX-315)，用於非黑素瘤皮膚癌，包括基底細胞癌和鱗狀細胞癌。請訪問了解更多信息。
FOR MORE INFORMATION, PLEASE CONTACT:
欲獲得更多信息，請聯繫:
Investors:
投資者：
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
凱文·加德納
生命科學顧問
kgardner@lifesciadvisors.com
Chris Calabrese
LifeSci Advisors
ccalabrese@lifesciadvisors.com
Chris Calabrese
生命科學顧問
ccalabrese@lifesciadvisors.com
譯文內容由第三人軟體翻譯。